載入...
Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity
Anthracyclines such as doxorubicin are highly effective chemotherapy agents used to treat many common malignancies. However, their use is limited by cardiotoxicity. We previously identified visnagin as protecting against doxorubicin toxicity in cardiac but not tumor cells. In this study, we sought t...
Na minha lista:
| 發表在: | JCI Insight |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society for Clinical Investigation
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5821184/ https://ncbi.nlm.nih.gov/pubmed/29321375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.96753 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|